Company Provectus Biopharmaceuticals, Inc. OTC Bulletin Board
Equities
PVCT
US74373P1084
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Immunotherapy Medicines
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | -43.61% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | -43.61% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Edward Pershing
CEO | Chief Executive Officer | 71 | 18-04-26 |
Eric A. Wachter
FOU | Founder | 61 | 01-12-31 |
Heather Raines
DFI | Director of Finance/CFO | 58 | 17-07-31 |
President | 55 | 17-04-02 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Eric A. Wachter
FOU | Founder | 61 | 01-12-31 |
John W. Lacey
BRD | Director/Board Member | 76 | 18-04-26 |
President | 55 | 17-04-02 | |
Edward Pershing
CEO | Chief Executive Officer | 71 | 18-04-26 |
Webster Bailey
BRD | Director/Board Member | 47 | 20-07-19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 10,361,097 | 0 | 0 | 90.58 % |
Stock B | 0 | 12,374,000 | 0 | 0 | |
Stock C | 1 | 419,522,119 | 379,994,922 ( 90.58 %) | 0 |
Company contact information
Provectus Biopharmaceuticals, Inc.
800 South Gay Street Suite 1610
37929, Knoxville
+866 594 5999
http://www.provectusbio.comSector
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- PVCT Stock
- PVCT Stock
- Company Provectus Biopharmaceuticals, Inc.